Market research
OPTN OptiNose
NASDAQ USD Healthcare
Latest close
As of 18 Jun 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- -0.89
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- -0.89
About
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Research context
OptiNose appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OPTN discussion.
5 years, 6 months ago
OptiNose, Inc is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
OptiNose, Inc's total revenue rose by 47.5% to $16M since the same quarter in the previous year.
Its net income has increased by 4.5% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.9% to $-19M since the same quarter in the previous year.
Based on the above factors, OptiNose, Inc gets an overall score of 3/5.